ArticleBioMed research international2015
Temozolomide and radiotherapy versus radiotherapy alone in high grade gliomas: a very long term comparative study and literature review.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Nanoparticle-Based Approaches for Glioblastoma Treatment: Advances and Future Prospects.CNS & neurological disorders drug targets · 2026Review
- Pneumocystis jirovecii pneumonia prophylaxis in patients with glioma receiving concurrent chemoradiation: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma.Cancer immunology research · 2025Article
- A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats.Clinical and translational radiation oncology · 2025Article
- Towards a New Dawn for Neuro-Oncology: Nanomedicine at the Service of Drug Delivery for Primary and Secondary Brain Tumours.Brain sciences · 2025Review
- Optimal fractionation scheme for lymphocyte infiltration in glioblastoma multiforme radiotherapy.Frontiers in oncology · 2025Article
- Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?Biomedicines · 2023Review
- Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study.Cancers · 2022Article
- Identification of a novel autophagy-related prognostic signature and small molecule drugs for glioblastoma by bioinformatics.BMC medical genomics · 2022Article
- Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay.Journal of biomedical physics & engineering · 2022Article
- Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.Future medicinal chemistry · 2021Review
- Translational gap in ongoing clinical trials for glioma.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2018Review
- Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients.Oncotarget · 2017Article
- Autophagy-related gene expression is an independent prognostic indicator of glioma.Oncotarget · 2017Article
- GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.Scientific reports · 2017Article
- Article
- Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.Oncotarget · 2016Article
- Retargeted adenoviruses for radiation-guided gene delivery.Cancer gene therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledTemozolomide (TMZ) is the first line drug in the care of high grade gliomas. The combined treatment of TMZ plus radiotherapy is more effective in the care of brain gliomas then radiotherapy alone. Aim of this report is a survival comparison, on a long time (>10 years) span, of glioma patients treated with radiotherapy alone and with radiotherapy + TMZ. MATERIALS AND
methodsIn this report we retrospectively reviewed the outcome of 128 consecutive pts with diagnosis of high grade gliomas referred to our institutions from April 1994 to November 2001. The first 64 pts were treated with RT alone and the other 64 with a combination of RT and adjuvant or concomitant TMZ.
resultsGrade 3 (G3) haematological toxicity was recorded in 6 (9%) of 64 pts treated with RT and TMZ. No G4 haematological toxicity was observed. Age, histology, and administration of TMZ were statistically significant prognostic factors associated with 2 years overall survival (OS). PFS was for GBM 9 months, for AA 11.
conclusionsThe combination of RT and TMZ improves long term survival in glioma patients. Our results confirm the superiority of the combination on a long time basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.